Related references
Note: Only part of the references are listed.Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer
Soumya Chatterjee et al.
CARCINOGENESIS (2021)
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
Marzia Del Re et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Zi Yin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
Qiao Yang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Rivka R. Colen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
R. Dziadziuszko et al.
ANNALS OF ONCOLOGY (2021)
PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis
Ji Chen et al.
CANCER SCIENCE (2021)
Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer
Mohammadhadi Khorrami et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
Wei Mu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
Marine Cordonnier et al.
JOURNAL OF EXTRACELLULAR VESICLES (2020)
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)
Alejandro Ruiz-Patino et al.
THORACIC CANCER (2020)
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
Marina Chiara Garassino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy.
Rivka R. Colen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Improving extracellular vesicles visualization: From static to motion
Pablo Reclusa et al.
SCIENTIFIC REPORTS (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
In vitro plant regeneration and Agrobacterium-mediated genetic transformation of a carnivorous plant, Nepenthes mirabilis
Sissi Miguel et al.
SCIENTIFIC REPORTS (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression
Malene Stochkel Frank et al.
LUNG CANCER (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
Dong Ha Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Liquid biopsy tracking of lung tumor evolutions over time
Alessandro Russo et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
C. Langer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
Marzia Del Re et al.
BRITISH JOURNAL OF CANCER (2018)
The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy
Andrea Anichini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes et al.
ONCOGENE (2018)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun et al.
LANCET ONCOLOGY (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Jung-Mao Hsu et al.
CANCER RESEARCH (2018)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging
Mahul B. Amin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer
Julie R. Brahmer
JOURNAL OF CLINICAL ONCOLOGY (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
